![](/img/cover-not-exists.png)
DOP52 Reduction in inflammatory biomarkers in a Phase 2 study of mirikizumab in patients with moderately to severely active ulcerative colitis
Sandborn, W J, Sands, B, Kobayashi, T, Tuttle, J, Schmitz, J, Durante, M, Higgs, R, Canavan, J B, Siegel, R, Ferrante, MVolume:
13
Journal:
Journal of Crohn's and Colitis
DOI:
10.1093/ecco-jcc/jjy222.086
Date:
January, 2019
File:
PDF, 689 KB
2019